{"id":1229,"date":"2025-04-29T15:58:42","date_gmt":"2025-04-29T14:58:42","guid":{"rendered":"https:\/\/helsinn-demo.it\/?page_id=1229"},"modified":"2025-05-20T14:00:19","modified_gmt":"2025-05-20T13:00:19","slug":"cancer-cachexia","status":"publish","type":"page","link":"https:\/\/helsinn-demo.it\/en_us\/technology\/therapeutic-areas\/cancer-cachexia\/","title":{"rendered":"Cancer Cachexia"},"content":{"rendered":"
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Cancer cachexia<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Cancer cachexia is a multifactorial, common but often underrecognized, debilitating clinical condition1-5<\/sup>, shown to adversely impact patients\u2019 tolerance and response to anticancer therapy5-9<\/sup>, as well as the survival of patients with advanced tumors9-14<\/sup>. Across all tumor types, more than 50% of patients with cancer develop cachexia, with a prevalence of up to 80% in patients with advanced cancers1<\/sup>; the condition has particularly high prevalence among patients with gastrointestinal (GI) and non-small cell lung cancers2<\/sup>. Cancer cachexia is often underrecognized, inadequately managed, and considered inevitable for patients with cancer3,4<\/sup>.<\/p>

Weight loss and anorexia are key clinical hallmarks of cancer cachexia17<\/sup>\u00a0correlated with shorter survival9-14<\/sup>; mortality among patients with cancer cachexia is estimated at 80%, with over 30% of deaths linked to cancer cachexia1<\/sup>. Weight and skeletal muscle mass loss are associated with metabolic dysfunction and cannot be fully reversed by conventional nutritional support16-17<\/sup>.<\/p>

Weight loss during cancer treatment has been associated with an increase in therapy-related toxicities5-8<\/sup>, negatively interfering with completion of therapy cycles15<\/sup>\u00a0and impairing response to cancer treatment9<\/sup>.<\/p>

Current treatment approaches for cancer cachexia have limited success18-21<\/sup>, with no available options to substantially improve LBM22<\/sup>\u00a0and potentially counteract the metabolic impairment associated with muscle depletion.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t

\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

References:\n<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
  1. \u00a0von Haehling S, Anker SD. J Cachexia Sarcopenia Muscle 2010;1:1<\/em>\u20135.<\/em><\/li>
  2. \u00a0Del Ferraro C, et al.\u00a0<\/em>J Hosp Palliat Nurs 2012;14.<\/em><\/li>
  3. \u00a0Benner A, et al. Support Care Cancer 2013;21(Suppl 1): abstract 0808.<\/em><\/li>
  4. \u00a0Muscaritoli M, et al. Ann Oncol 2016;27:2230<\/em>\u20132236.<\/em><\/li>
  5. \u00a0Fukahori M, et al. Support Care Cancer 2021;29:341\u2013348.<\/em><\/li>
  6. da Rocha IMG, et al. J Cachexia Sarcopenia Muscle 2019;10:445\u2013454.<\/em><\/li>
  7. \u00a0Mitsunaga S, et al. Support Care Cancer 2020;28:5271\u20135279.<\/em><\/li>
  8. \u00a0Molfino A, et al. Clin Nutr 2021;\u00a0<\/em>https:\/\/doi.org\/10.1016\/j.clnu.2021.02.016<\/em><\/a>.<\/em><\/li>
  9. \u00a0Roch B, et al. Lung Cancer 2020;143:19\u201326.<\/em><\/li>
  10. \u00a0Gallois C, et al. Clin Res Hepatol Gastroenterol 2021;45:101603.<\/em><\/li>
  11. \u00a0Guercio BJ, et al. JNCI Cancer Spectr 2020;4:pkaa024.<\/em><\/li>
  12. Kim KW, et al. BMC Cancer 2021;21:157.<\/em><\/li><\/ol>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

    Cancer cachexia Cancer cachexia is a multifactorial, common but often underrecognized, debilitating clinical condition1-5, shown to adversely impact patients\u2019 tolerance and response to anticancer therapy5-9, as well as the survival of patients with advanced tumors9-14. Across all tumor types, more than 50% of patients with cancer develop cachexia, with a prevalence of up to 80% […]<\/p>","protected":false},"author":1,"featured_media":0,"parent":1218,"menu_order":5,"comment_status":"closed","ping_status":"closed","template":"elementor_header_footer","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-1229","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/helsinn-demo.it\/en_us\/wp-json\/wp\/v2\/pages\/1229","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/helsinn-demo.it\/en_us\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/helsinn-demo.it\/en_us\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/helsinn-demo.it\/en_us\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/helsinn-demo.it\/en_us\/wp-json\/wp\/v2\/comments?post=1229"}],"version-history":[{"count":4,"href":"https:\/\/helsinn-demo.it\/en_us\/wp-json\/wp\/v2\/pages\/1229\/revisions"}],"predecessor-version":[{"id":1515,"href":"https:\/\/helsinn-demo.it\/en_us\/wp-json\/wp\/v2\/pages\/1229\/revisions\/1515"}],"up":[{"embeddable":true,"href":"https:\/\/helsinn-demo.it\/en_us\/wp-json\/wp\/v2\/pages\/1218"}],"wp:attachment":[{"href":"https:\/\/helsinn-demo.it\/en_us\/wp-json\/wp\/v2\/media?parent=1229"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}